Clinical trial

A Phase 2b, Multicenter, Randomized, Double-masked Vehicle-controlled Study to Evaluate the Efficacy and Safety of TL-925 Ophthalmic Emulsion 0.1% in Subjects With Moderate to Severe Dry Eye Disease

Name
TL-925-303
Description
In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 670 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or vehicle as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: a two-week screening phase/run-in and a six-week double-masked treatment phase.
Trial arms
Trial start
2024-02-06
Estimated PCD
2024-12-01
Trial end
2024-12-01
Status
Recruiting
Phase
Early phase I
Treatment
TL-925
TL-925 is an eye drop.
Arms:
TL-925 Arm
Placebo
The composition of the vehicle is identical to the active formulation except for the exclusion of the active ingredient.
Arms:
Vehicle Arm
Size
670
Primary endpoint
To evaluate the efficacy of TL-925 compared to vehicle on tear production
Baseline to Day 29
Eligibility criteria
Inclusion Criteria: * A diagnosis of dry eye disease for at least 6 months * An unanesthetized Schirmer's test score (STS) of ≤ 10mm and ≥ 1mm in the study eye * Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study Exclusion Criteria: * Any clinically significant slit lamp finding * Any ongoing ocular infection (bacterial, viral or fungal) or active ocular inflammation * Best-corrected visual acuity ≥0.7 logarithm of the minimum angle of resolution * Any keratorefractive surgery within the last 12 months * Any intraocular or extraocular surgery within 3 months * Any blepharoplasty or corneal transplant in either eye * Any form of punctual, or intracanalicular occlusion in either eye * History or presence of any ocular disorder that may interfere with study results
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'maskingDescription': 'The Sponsor, Investigators and study staff will be masked during the randomization process and throughout the study. The study site will have the capacity to unmask participants in an emergency.\n\nFollowing completion of the study, the randomization code will be unmasked once all data has been entered into the study database for every subject and the database has been locked.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 670, 'type': 'ESTIMATED'}}
Updated at
2024-03-15

1 organization

1 product

1 indication

Organization
Telios Pharma
Product
TL-925